FI970990A - Syövän toteaminen ja hoito - Google Patents
Syövän toteaminen ja hoito Download PDFInfo
- Publication number
- FI970990A FI970990A FI970990A FI970990A FI970990A FI 970990 A FI970990 A FI 970990A FI 970990 A FI970990 A FI 970990A FI 970990 A FI970990 A FI 970990A FI 970990 A FI970990 A FI 970990A
- Authority
- FI
- Finland
- Prior art keywords
- patient
- afp
- cancer cells
- introducing
- labeled
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 15
- 201000011510 cancer Diseases 0.000 title abstract 15
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 10
- 102000005962 receptors Human genes 0.000 abstract 10
- 108020003175 receptors Proteins 0.000 abstract 10
- 239000012472 biological sample Substances 0.000 abstract 3
- 239000012620 biological material Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30814194A | 1994-09-19 | 1994-09-19 | |
| US30814194 | 1994-09-19 | ||
| IB9500902 | 1995-09-18 | ||
| PCT/IB1995/000902 WO1996009551A1 (en) | 1994-09-19 | 1995-09-18 | Detection and treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI970990A0 FI970990A0 (fi) | 1997-03-10 |
| FI970990A true FI970990A (fi) | 1997-03-10 |
| FI121353B FI121353B (fi) | 2010-10-15 |
Family
ID=23192727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI970990A FI121353B (fi) | 1994-09-19 | 1997-03-10 | Menetelmä syöpäkasvaimen havaitsemiseksi |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6514685B1 (fi) |
| EP (3) | EP0782709B1 (fi) |
| KR (1) | KR970706498A (fi) |
| CN (2) | CN100472213C (fi) |
| AT (1) | ATE449342T1 (fi) |
| AU (1) | AU714966B2 (fi) |
| BR (1) | BR9508959A (fi) |
| CA (1) | CA2197490A1 (fi) |
| DE (1) | DE69536019D1 (fi) |
| DK (1) | DK0782709T3 (fi) |
| ES (1) | ES2336976T3 (fi) |
| FI (1) | FI121353B (fi) |
| NO (1) | NO323754B1 (fi) |
| RU (1) | RU2161042C2 (fi) |
| WO (1) | WO1996009551A1 (fi) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
| AU2003216048A1 (en) * | 2002-01-10 | 2003-07-30 | David Kleinfeld | Iterative optical based histology |
| US7638270B2 (en) * | 2003-01-24 | 2009-12-29 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
| CN100360684C (zh) * | 2005-02-01 | 2008-01-09 | 合肥中科大生物技术有限公司 | 甲胎蛋白(AFP)mRNA荧光定量RT-PCR检测试剂盒 |
| EP2118123B1 (en) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| WO2008121767A2 (en) | 2007-03-28 | 2008-10-09 | President And Fellows Of Harvard College | Stitched polypeptides |
| PL2322221T3 (pl) | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| HUE027332T2 (en) | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| US9186128B2 (en) * | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
| US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
| US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
| US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
| US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
| EP2480565A4 (en) | 2009-09-22 | 2014-01-01 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| US20120270238A1 (en) * | 2009-10-22 | 2012-10-25 | Moro Ricardo J | Peptides That Bind the Alpha-Fetoprotein (AFP) Receptor and Uses Thereof |
| US9180187B2 (en) * | 2010-02-04 | 2015-11-10 | Toray Industries, Inc. | Medicament for treating and/or preventing cancer |
| EP2889295A1 (en) | 2010-08-12 | 2015-07-01 | New York University | Oligooxopiperazines and methods of making and using them |
| WO2012021876A2 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| RU2624040C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Способ обнаружения рака поджелудочной железы |
| AU2012326026B2 (en) | 2011-10-18 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
| US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| CN104334541A (zh) | 2012-02-16 | 2015-02-04 | 纽约大学 | 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制 |
| PL2876446T3 (pl) | 2012-07-19 | 2019-06-28 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
| US9862774B2 (en) | 2013-08-09 | 2018-01-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| WO2017079442A1 (en) | 2015-11-04 | 2017-05-11 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
| US11246868B2 (en) | 2016-04-26 | 2022-02-15 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
| CN106290876B (zh) * | 2016-08-11 | 2018-06-29 | 湖南新大陆生物技术有限公司 | 一种肿瘤细胞检测方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2701710B1 (fr) * | 1993-02-18 | 1995-04-21 | Intromed Ltd | Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic. |
-
1995
- 1995-09-18 DK DK95940906.1T patent/DK0782709T3/da active
- 1995-09-18 EP EP95940906A patent/EP0782709B1/en not_active Expired - Lifetime
- 1995-09-18 RU RU97106059/14A patent/RU2161042C2/ru not_active IP Right Cessation
- 1995-09-18 DE DE69536019T patent/DE69536019D1/de not_active Expired - Lifetime
- 1995-09-18 WO PCT/IB1995/000902 patent/WO1996009551A1/en not_active Application Discontinuation
- 1995-09-18 EP EP08002690A patent/EP1956374A1/en not_active Withdrawn
- 1995-09-18 KR KR1019970701775A patent/KR970706498A/ko not_active Application Discontinuation
- 1995-09-18 CN CNB200310104769XA patent/CN100472213C/zh not_active Expired - Fee Related
- 1995-09-18 ES ES95940906T patent/ES2336976T3/es not_active Expired - Lifetime
- 1995-09-18 EP EP08002689A patent/EP1955714A1/en not_active Withdrawn
- 1995-09-18 AT AT95940906T patent/ATE449342T1/de not_active IP Right Cessation
- 1995-09-18 BR BR9508959A patent/BR9508959A/pt not_active Application Discontinuation
- 1995-09-18 CN CN95195125A patent/CN1132012C/zh not_active Expired - Fee Related
- 1995-09-18 CA CA002197490A patent/CA2197490A1/en not_active Abandoned
- 1995-09-18 AU AU37648/95A patent/AU714966B2/en not_active Ceased
-
1997
- 1997-03-10 FI FI970990A patent/FI121353B/fi not_active IP Right Cessation
- 1997-03-18 NO NO19971256A patent/NO323754B1/no not_active IP Right Cessation
- 1997-08-15 US US08/920,654 patent/US6514685B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK0782709T3 (da) | 2010-03-29 |
| FI121353B (fi) | 2010-10-15 |
| CN1169778A (zh) | 1998-01-07 |
| RU2161042C2 (ru) | 2000-12-27 |
| EP1955714A1 (en) | 2008-08-13 |
| EP0782709B1 (en) | 2009-11-18 |
| NO971256L (no) | 1997-03-18 |
| CN1132012C (zh) | 2003-12-24 |
| EP1956374A1 (en) | 2008-08-13 |
| EP0782709A1 (en) | 1997-07-09 |
| FI970990A0 (fi) | 1997-03-10 |
| NO323754B1 (no) | 2007-07-02 |
| CN100472213C (zh) | 2009-03-25 |
| AU3764895A (en) | 1996-04-09 |
| CN1502994A (zh) | 2004-06-09 |
| WO1996009551A1 (en) | 1996-03-28 |
| NO971256D0 (no) | 1997-03-18 |
| ATE449342T1 (de) | 2009-12-15 |
| KR970706498A (ko) | 1997-11-03 |
| ES2336976T3 (es) | 2010-04-19 |
| DE69536019D1 (de) | 2009-12-31 |
| AU714966B2 (en) | 2000-01-13 |
| BR9508959A (pt) | 1997-12-30 |
| US6514685B1 (en) | 2003-02-04 |
| CA2197490A1 (en) | 1996-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI970990A (fi) | Syövän toteaminen ja hoito | |
| NO904001D0 (no) | Fremgangsmaate og anordning for amperometrisk diagnoseanalyse. | |
| DE69910007D1 (de) | Vorrichtung zum vorhersagen von physiologischen messwerten | |
| ATE159982T1 (de) | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung | |
| DE69733560D1 (de) | TESTVERFAHREN UND REAGENZIEN ZUR QUANTIFIZIERUNG VON hBNP | |
| DE69723860D1 (de) | VERFAHREN ZUR BESTIMMUNG VON IgE | |
| RU97106059A (ru) | Обнаружение и лечение рака | |
| ATE129868T1 (de) | Vorrichtung und verfahren zum nachweis von chemischen spezies. | |
| DE69631738D1 (de) | Medizinische implantierbare Vorrichtung für elektrochemische Messungen von Bluteigenschaften | |
| ATE394658T1 (de) | Spurendetektion von analyten mit hilfe artifizieller olfaktometrie | |
| ATE137583T1 (de) | Verfahren und vorrichtung zur bestimmung von chemischen spezies in körperflüssigkeit | |
| ATE315789T1 (de) | Elisa für vegf | |
| ATE126354T1 (de) | Vorrichtung und verfahren zur bestimmung eines analyten in einer flüssigen probe mittels folgereaktionen. | |
| ES2121358T3 (es) | Anticuerpos monoclonales humanizados contra interleuquina-4 humana. | |
| DE3856004D1 (de) | Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie | |
| DE60025170D1 (de) | Diagnostisches verfahren für asthma | |
| DE3485265D1 (de) | Verfahren zur bestimmung eines polyvalenten antigens und reagenz hierfuer. | |
| ATE365921T1 (de) | Immunologische zusammensetzung zum nachweis von blasenkrebs und verfahren zu ihrer verwendung | |
| DE69531505D1 (de) | Verfahren zur zellerkennung | |
| ATE208040T1 (de) | Immunoassay-reagenzien, testsätze und verfahren | |
| Ottó | Simple screening of Bence-Jones proteins from unconcentrated urine | |
| DePhilippis et al. | Reducing Subject Attrition in Drug Abuse Studies: Identifying Attrition Risk Factors and Techniques to Improve Follow-up | |
| ATE195183T1 (de) | Methode zur bestimmung einer substanz | |
| RU2000103679A (ru) | Неинвазивный способ выявления helicobacter pylori при язвенной болезни двенадцатиперстной кишки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 121353 Country of ref document: FI |
|
| MM | Patent lapsed |